Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · IEX Real-Time Price · USD
1.810
+0.080 (4.62%)
At close: May 3, 2024, 4:00 PM
1.840
+0.030 (1.66%)
After-hours: May 3, 2024, 4:41 PM EDT
Perspective Therapeutics Revenue
In the year 2023, Perspective Therapeutics had annual revenue of $1.43M. Revenue in the quarter ending December 31, 2023 was $-4.90M with 185.50% year-over-year growth.
Revenue (ttm)
$1.43M
Revenue Growth
-126.65%
P/S Ratio
728.53
Revenue / Employee
$12,362
Employees
116
Market Cap
1.06B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.43M | - | - |
Jun 30, 2022 | 0 | - | - |
Jun 30, 2021 | 10.05M | 373.00K | 3.85% |
Jun 30, 2020 | 9.68M | 2.37M | 32.35% |
Jun 30, 2019 | 7.31M | 1.39M | 23.48% |
Jun 30, 2018 | 5.92M | 1.16M | 24.41% |
Jun 30, 2017 | 4.76M | -8.00K | -0.17% |
Jun 30, 2016 | 4.77M | 163.00K | 3.54% |
Jun 30, 2015 | 4.61M | 386.84K | 9.17% |
Jun 30, 2014 | 4.22M | -306.08K | -6.76% |
Jun 30, 2013 | 4.53M | -545.86K | -10.76% |
Jun 30, 2012 | 5.07M | -167.89K | -3.20% |
Jun 30, 2011 | 5.24M | -47.11K | -0.89% |
Jun 30, 2010 | 5.29M | -131.73K | -2.43% |
Jun 30, 2009 | 5.42M | -1.74M | -24.32% |
Jun 30, 2008 | 7.16M | 1.42M | 24.76% |
Jun 30, 2007 | 5.74M | 3.74M | 187.72% |
Jun 30, 2006 | 1.99M | 1.79M | 888.60% |
Jun 30, 2005 | 201.73K | - | - |
Sep 30, 2004 | 0 | - | - |
Sep 30, 2003 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Alignment Healthcare | 2.01B |
AtriCure | 414.60M |
MiMedx Group | 334.51M |
Cronos Group | 87.24M |
Immatics | 60.00M |
Arcutis Biotherapeutics | 59.61M |
EyePoint Pharmaceuticals | 46.02M |
Bicycle Therapeutics | 41.61M |
CATX News
- 10 hours ago - Perspective Therapeutics to Participate at Upcoming May Investor Conferences - GlobeNewsWire
- 1 day ago - Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results - GlobeNewsWire
- 3 days ago - Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs - GlobeNewsWire
- 25 days ago - Perspective Therapeutics to Participate at Upcoming April Investor Conferences - GlobeNewsWire
- 5 weeks ago - Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Perspective Therapeutics Announces $87.4 Million Private Placement - GlobeNewsWire
- 3 months ago - Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform - GlobeNewsWire
- 3 months ago - Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement - GlobeNewsWire